DarshanTalks Podcast

Send us Fan Mail

Katie Graham and I discuss various aspects of FDA and FTC regulations, including ad promo, the Chevron decision, and the evolving role of compliance in the pharmaceutical industry.
Key topics include:

1. What is Ad Promo?
2. Chevron decision's influence on FDA/FTC
3. Should administrative agencies cite letters? 
4. Can the FDA establish rules after someone challenges them?
5. Uncertainty of Compliance White Space
6. Is regulatory medical advice now just seen as a risk?

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Training your research site staff is critical. Despite regulations requiring Principal Investigators (PIs) to ensure proper training for research staff, recent cases reveal significant lapses. PIs are responsible for certifying that all associates, colleagues, and employees involved in the research are adequately trained and informed. However, instances have emerged where this responsibility was neglected.

In one notable case, PIs were prosecuted due to inadequate training and oversight of research staff. Study coordinators, often without relevant research experience and from low-wage backgrounds, were left to manage studies without proper guidance. This lack of training led to errors and potential fraud, highlighting a crucial gap in compliance.

Ensuring that all research staff are properly trained is essential for the integrity of clinical trials. If you need help developing a robust clinical research program, reach out to me. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Neuralink recently received the FDA's Breakthrough Device label for its neural implant aimed at restoring vision to the blind by interfacing with the brain. While this sounds like a monumental achievement, it's important to understand that the Breakthrough Device program merely expedites the review process for promising innovations without guaranteeing approval or effectiveness. Essentially, this label serves more as a marketing badge than a concrete breakthrough at this stage. While there's hope for the technology's potential, it's crucial to remain skeptical and not let flashy terms cloud judgment. Real-world results are still a significant distance away.  

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

DOJ filed criminal charges against 193 defendants, including 76 medical professionals for telemedicine violation. This alarming crackdown reveals the vulnerabilities within telemedicine, as illegal kickbacks and brief consultations have led to significant fraud, particularly in Medicare claims.

Among the troubling cases highlighted, one psychiatrist was accused of billing for telehealth visits lasting only 10 to 30 seconds, falsely classified as legitimate patient consultations. The DOJ’s focus on these practices serves as a critical reminder that telehealth providers must adhere to stringent federal and state regulations to avoid legal repercussions, including criminal charges and loss of medical licenses.

Healthcare practitioners are urged to ensure their telehealth practices are not only clinically sound but also compliant with legal standards. For those in the telehealth space, seeking legal guidance is paramount to safeguarding their practices and upholding patient care standards. The Kulkarni Law Firm is available to assist healthcare professionals in navigating these challenges and avoiding potential fraud schemes.

As the telemedicine landscape evolves, it's vital to consider whether the convenience of remote consultations outweighs the increased scrutiny and risks associated with them. Join the conversation by sharing your thoughts on the future of telehealth in the comments below.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Heather McFalls discusses the pros and cons of in-house versus outsourced advertising compliance roles, along with tips for new regulatory professionals to embed themselves and add value. They also explore how the shift from FDA to FTC oversight may impact Ad Promo training and mentorship.

We discuss,
1.    Role as a Director of Advertising & Promotion. 
2.    Is this job typically done in-house, or is it often outsourced? 
3.    What are the biggest advantages and disadvantages of using in-house staff for ad promo? 
4.    What are the pros and cons of using outside contractors for ad promo? 
5.    How does one get embedded as a contractor or as a full-time employee? 
6.    What advice do you have for new regulatory professionals to become more embedded and add value?
7.    Is the shift from FDA to FTC letters affecting ad promo training? 
8.    Opportunity of mentorship for newer reviewers 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Nature and Vox highlight the severe consequences of research fraud and its widespread impact on sectors like marketing, clinical research, medical affairs, regulatory compliance, and legal practices. Fraud can manifest in various ways, such as fabricating data or manipulating results, and its effects are far-reaching.

The Nature article stresses that fraudulent research erodes public trust in science and endangers patient safety, especially in the pharmaceutical and medical device industries, where fraud can lead to legal issues, financial losses, and reputational damage. For marketers and medical affairs teams, relying on invalid clinical data can result in severe regulatory penalties and brand damage.

Clinical researchers and physicians face additional risks, as relying on faulty research for treatment decisions could harm patients, leading to legal liabilities. Regulatory professionals and life sciences attorneys must stay vigilant in identifying red flags in research to advise clients on avoiding compliance pitfalls.

At Kulkarni Law Firm, we focus on FDA regulatory compliance, clinical research, and pharmaceutical advertising law. Reach out to us today to ensure your work remains compliant and beyond reproach.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Influencers are NOT KOLs. We discuss using key opinion leaders (KOLs) and influencers in pharmaceutical and medical device marketing. 

Key Takeaways:

- Influencers vs. KOLs: Influencers have large social media followings and can engage younger demographics, while KOLs are respected experts whose endorsements are based on scientific evidence.

- Benefits and Risks: Influencers can create relatable content but risk non-compliance, while KOLs offer credibility but may deliver more conservative messages.

Best Practices:

  - Align with influencers and KOLs who match your target audience.

  - Ensure understanding of regulatory requirements.

  - Conduct thorough vetting and provide training.

  - Establish clear contracts and monitor content for compliance.

 For Life Sciences Attorneys:

It's vital to review contracts, monitor content, and collaborate with marketing teams to protect company interests.

For more insights, subscribe to our podcast and reach out to the Kulkarni Law Firm for guidance on navigating influencer campaigns while minimizing legal risks.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, we’re diving into a crucial topic: the role of artificial intelligence in clinical research and the evolving landscape of data privacy laws that will impact every step of the process.

In this episode, we’ll be unpacking insights from Dr. ElZarrad, the FDA’s Deputy Director for the Office of Medical Policy, on how AI is shaping clinical trial design and research. We’ll also explore how AI can speed up trials, enhance patient recruitment, and even predict outcomes with greater accuracy. But with these advancements comes a significant responsibility, especially when it comes to patient data privacy. We'll talk about how laws like HIPAA, GDPR, CCPA, and others play a crucial role in safeguarding sensitive patient data at every step of AI development.

If you're as passionate about the future of clinical research as we are, hit **like, subscribe, and share—it really helps grow the channel!

Now, let’s start from the beginning: Why is AI such a game-changer in clinical research? Well, it enables researchers to analyze vast datasets quickly, allowing for more tailored, personalized therapies. It’s a breakthrough for precision medicine and personalized healthcare, and if we get this right, it could transform the entire industry. 

Dr. Dr. ElZarrad from the FDA highlights how AI can identify eligible patients more effectively and analyze real-time data, speeding up clinical trials significantly. AI also supports the rise of decentralized trials, where patients can participate remotely, making trials more accessible and diverse. This shift will be crucial, especially given the recent clinical trials guidance and the growing role of telemedicine.

Of course, with this technological power comes the critical need for transparency and patient consent. AI relies heavily on sensitive data like medical histories, genetic information, and treatment responses. We’ll also dive into the different layers of privacy laws—from data collection to tracking and communication regulations—and discuss why ensuring compliance at every stage is essential for maintaining trust and avoiding major legal pitfalls.

Stay tuned as we break down these complexities and offer practical tips for staying compliant in this ever-evolving space.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Eli Lilly's changed its opinion on Off-Label uses! Eli Lilly, a company that makes a diabetes drug, is now urging people not to use it for weight loss, a common off-label use, despite not raising concerns about off-label uses in the past. Off-label use, where a drug is used for something other than its original purpose, is a normal part of healthcare, and the FDA acknowledges this practice. However, Lilly's sudden stance seems driven by a shortage of the drug, which they want to prioritize for diabetes patients. This shift appears more about supply management than safety. It's crucial that companies and regulatory bodies maintain consistent messaging to avoid confusion and ensure patient care remains a priority.

 Let's continue advocating for what's best for patients.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Isaac Rodriguez- Chavez and I discuss the impact of DCTs on sponsor relationships, CROs, and industry dynamics with the FDA. 

We discuss,

1. How will DCTs impact sponsor relationships with CROs? 

2. How do small CROs and sponsors adapt to emerging trends? 

3. How do new trends impact industry relationships with the FDA?

4. Does DCT allows the FDA to advise sponsors? 

5. What is the role of technology in DCTs? 

6. How do DCTs reduce the cost of bringing drugs to the market? 

7.  What are the risks and advantages of DCTs? 

8. What are the initial risks of DCTs? 

9.  Does the FDA even have jurisdiction over patient privacy? 

Support the show

www.kulkarnilawfirm.com